Bioequivalence Across 3 Different Injection Site [Power / Sample Size]

posted by XH7081 – 2022-09-21 22:22 (635 d 20:05 ago) – Posting: # 23311
Views: 2,831

Hello! First of all thank you for the wonderful PowerTOST package!

If I want to design an injection site study to compare the relative bioavailability at 3 different injection site, say T1, T2 vs R, in either crossover design or parallel design, is it correct to use the R code below:

1. Crossover design (3x6x3), assuming true theta=1, intra-CV=0.3. R results indicate I need 42 total subjects (7 subjects per sequence), not considering drop out etc. Is it correct?

> sampleN.TOST(theta0=1, CV=0.3, design="3x6x3",targetpower=0.9)

+++++++++++ Equivalence test - TOST +++++++++++
Sample size estimation
-----------------------------------------------
Study design: 3x6x3 crossover
log-transformed data (multiplicative model)

alpha = 0.05, target power = 0.9
BE margins = 0.8 ... 1.25
True ratio = 1, CV = 0.3

Sample size (total)
n power
42 0.929519

I also saw some posts suggest doing "two at a time" test, which will use the 2x2 design as follows (which gave essentially the same sample size as the 3x6x3 design above since I need to round up to 6X, so 40 becomes 42). Is this thought process correct?

> sampleN.TOST(theta0=1, CV=0.3, design="2x2",targetpower=0.9)

+++++++++++ Equivalence test - TOST +++++++++++
Sample size estimation
-----------------------------------------------
Study design: 2x2 crossover
log-transformed data (multiplicative model)

alpha = 0.05, target power = 0.9
BE margins = 0.8 ... 1.25
True ratio = 1, CV = 0.3

Sample size (total)
n power
40 0.909560


2. Parallel design (3 arms, assuming true theta=1, pooled CV=0.4). R results indicate I need 132 total subjects (44 subjects per arm), not considering drop out etc. Is it correct, or the 132 is for 2 arms (66 per arm) and I actually need 198 total subjects?

> sampleN.TOST(alpha = 0.05,
+ CV = 0.40, theta0 = 1,
+ targetpower = 0.90, design = "parallel")

+++++++++++ Equivalence test - TOST +++++++++++
Sample size estimation
-----------------------------------------------
Study design: 2 parallel groups
log-transformed data (multiplicative model)

alpha = 0.05, target power = 0.9
BE margins = 0.8 ... 1.25
True ratio = 1, CV = 0.4

Sample size (total)
n power
132 0.904103


Many thanks!

Complete thread:

UA Flag
Activity
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
105 visitors (0 registered, 105 guests [including 8 identified bots]).
Forum time: 18:28 CEST (Europe/Vienna)

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5